Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

1.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R.

J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26.

PMID:
22454421
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.

Forero-Torres A, Fanale M, Advani R, Bartlett NL, Rosenblatt JD, Kennedy DA, Younes A.

Oncologist. 2012;17(8):1073-80. doi: 10.1634/theoncologist.2012-0133. Epub 2012 Aug 1.

PMID:
22855426
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A.

J Clin Oncol. 2012 Jun 20;30(18):2190-6. doi: 10.1200/JCO.2011.38.0402. Epub 2012 May 21.

PMID:
22614995
[PubMed - indexed for MEDLINE]
4.

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM.

Lancet Oncol. 2013 Dec;14(13):1348-56. doi: 10.1016/S1470-2045(13)70501-1. Epub 2013 Nov 15.

PMID:
24239220
[PubMed - indexed for MEDLINE]
5.

Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.

Bradley AM, Devine M, DeRemer D.

Am J Health Syst Pharm. 2013 Apr 1;70(7):589-97. doi: 10.2146/ajhp110608. Review.

PMID:
23515511
[PubMed - indexed for MEDLINE]
6.

A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies.

Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, Han TH, Sievers EL, Bartlett NL.

Clin Cancer Res. 2012 Jan 1;18(1):248-55. doi: 10.1158/1078-0432.CCR-11-1425. Epub 2011 Nov 11.

PMID:
22080439
[PubMed - indexed for MEDLINE]
Free Article
7.

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.

Han TH, Chen R, Advani R, Berryman RB, Smith SE, Forero-Torres A, Rosenblatt JD, Smith MR, Zain J, Hunder NN, Engert A.

Cancer Chemother Pharmacol. 2013 Jul;72(1):241-9. doi: 10.1007/s00280-013-2192-z. Epub 2013 May 30.

PMID:
23719719
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.

Minich SS.

Ann Pharmacother. 2012 Mar;46(3):377-83. doi: 10.1345/aph.1Q680. Epub 2012 Mar 6. Review.

PMID:
22395252
[PubMed - indexed for MEDLINE]
9.

Brentuximab vedotin for the treatment of CD30+ lymphomas.

Foyil KV, Bartlett NL.

Immunotherapy. 2011 Apr;3(4):475-85. doi: 10.2217/imt.11.15. Review.

PMID:
21463188
[PubMed - indexed for MEDLINE]
10.

Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.

Ogura M, Tobinai K, Hatake K, Ishizawa K, Uike N, Uchida T, Suzuki T, Aoki T, Watanabe T, Maruyama D, Yokoyama M, Takubo T, Kagehara H, Matsushima T.

Cancer Sci. 2014 May 11. doi: 10.1111/cas.12435. [Epub ahead of print]

PMID:
24814862
[PubMed - as supplied by publisher]
11.

Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma.

Sasse S, Rothe A, Goergen H, Eichenauer DA, Lohri A, Kreher S, Jäger U, Bangard C, Kuhnert G, Böll B, von Tresckow B, Engert A.

Leuk Lymphoma. 2013 Oct;54(10):2144-8. doi: 10.3109/10428194.2013.775434. Epub 2013 Mar 27.

PMID:
23402268
[PubMed - indexed for MEDLINE]
12.

Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.

Newland AM, Li JX, Wasco LE, Aziz MT, Lowe DK.

Pharmacotherapy. 2013 Jan;33(1):93-104. doi: 10.1002/phar.1170. Review.

PMID:
23307550
[PubMed - indexed for MEDLINE]
13.

Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?

Goyal SD, Bartlett NL.

Curr Hematol Malig Rep. 2012 Sep;7(3):179-85. doi: 10.1007/s11899-012-0126-1. Review.

PMID:
22669711
[PubMed - indexed for MEDLINE]
14.

Brentuximab vedotin in systemic T-cell lymphoma.

Oki Y, Younes A.

Expert Opin Biol Ther. 2012 May;12(5):623-32. doi: 10.1517/14712598.2012.670216. Epub 2012 Mar 20.

PMID:
22428917
[PubMed - indexed for MEDLINE]
15.

Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.

Gualberto A.

Expert Opin Investig Drugs. 2012 Feb;21(2):205-16. doi: 10.1517/13543784.2011.641532. Epub 2011 Nov 30. Review.

PMID:
22127011
[PubMed - indexed for MEDLINE]
16.

U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B, Ouyang Y, Saber H, Lee K, Koti K, Rothmann M, Shapiro M, Borrego F, Clouse K, Chen XH, Brown J, Akinsanya L, Kane R, Kaminskas E, Farrell A, Pazdur R.

Clin Cancer Res. 2012 Nov 1;18(21):5845-9. doi: 10.1158/1078-0432.CCR-12-1803. Epub 2012 Sep 7.

PMID:
22962441
[PubMed - indexed for MEDLINE]
Free Article
17.

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.

Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, Siddiqi T, Kennedy DA, Oki Y.

Blood. 2014 May 15;123(20):3095-100. doi: 10.1182/blood-2013-12-542142. Epub 2014 Mar 20.

PMID:
24652992
[PubMed - in process]
18.

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.

Gopal AK, Ramchandren R, O'Connor OA, Berryman RB, Advani RH, Chen R, Smith SE, Cooper M, Rothe A, Matous JV, Grove LE, Zain J.

Blood. 2012 Jul 19;120(3):560-8. doi: 10.1182/blood-2011-12-397893. Epub 2012 Apr 17.

PMID:
22510871
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.

Rothe A, Sasse S, Goergen H, Eichenauer DA, Lohri A, Jäger U, Bangard C, Böll B, von Bergwelt Baildon M, Theurich S, Borchmann P, Engert A.

Blood. 2012 Aug 16;120(7):1470-2. doi: 10.1182/blood-2012-05-430918. Epub 2012 Jul 11.

PMID:
22786877
[PubMed - indexed for MEDLINE]
Free Article
20.

[Brentuximab vedotin: new treatment for CD30+ lymphomas].

Terriou L, Bonnet S, Debarri H, Demarquette H, Morschhauser F.

Bull Cancer. 2013 Jul-Aug;100(7-8):775-9. doi: 10.1684/bdc.2013.1778. Review. French.

PMID:
23831822
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk